For Immediate Release
Chicago, IL – June 30, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Meta Platforms, Inc. (
META Quick Quote META - Free Report) , Eli Lilly and Co. ( LLY Quick Quote LLY - Free Report) , The Home Depot, Inc. ( HD Quick Quote HD - Free Report) , The Boeing Company ( BA Quick Quote BA - Free Report) , and Vale S.A. ( VALE Quick Quote VALE - Free Report) Here are highlights from Wednesday’s Analyst Blog: Top Analyst Reports for Meta Platforms, Eli Lilly and Home Depot
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc., Eli Lilly and Co., and The Home Depot, Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>> Meta Platforms shares have held up better relative to the Zacsk Internet Services industry over the past year (down -53.8% vs. -64.0% for the industry), but it has lagged the broader market in a major way (down -53.8% vs. -11.6% for the S&P 500 index).
In addition to market wide sentiment shifts about the Tech sector in general in the current rising interest rate environment, Meta is suffering from Apple's iOS changes as well as engagement-related headwinds. Apple's iOS changes have made ad targeting difficult, which, in turn, has increased the cost of driving outcomes. Measuring these outcomes has also become difficult. Meta expects these factors to hurt advertising revenue growth throughout 2022. Meta's second-quarter guidance reflects macroeconomic and forex concerns.
Cost inflation and supply chain disruptions are expected to impact advertiser budgets. However, Meta is benefiting from steady user growth across all regions, particularly Asia Pacific. Increased engagement for its products like Instagram, WhatsApp, Messenger and Facebook has been a major growth driver.
) read the full research report on Meta Platforms here >>> Eli Lilly shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+40.4% vs. +19.8%), reflecting the company's solid portfolio of core drugs in diabetes, autoimmune diseases and cancer. The Zacks analyst believes that Lilly's revenue growth is being driven by higher demand for drugs like Trulicity, Taltz, and others. It is regularly adding promising new pipeline assets through business development deals.
It has an exciting pipeline of potential new medicines including tirzepatide for type II diabetes and donanemab for early Alzheimer's disease. Both candidates have multibillion dollar sales potential. However, generic competition for several drugs, rising pricing pressure in the United States mainly on key drug, Trulicity, and price cuts in some international markets like China, Japan and Europe are some top-line headwinds.
) read the full research report on Eli Lilly here >>> Home Depot shares have declined -13.4% over the past year against Zacks Building Products - Retail industry's decline of -11.2% and the S&P 500 index's -11.6% decline. The company reported soft gross margin in the fiscal first quarter driven by higher cost of goods sold. Supply chain headwinds also marred results to some extent. Nevertheless, Home Depot boasts a robust surprise trend, which continued in first-quarter fiscal 2022. Results gained from strong demand for home-improvement projects, robust housing market trends and ongoing investments.
The company also benefited from continued strength in both Pro and DIY categories as well as digital momentum. Its interconnected retail strategy and underlying technology infrastructure have helped consistently boost web traffic for the past few quarters, aiding digital sales.
) read the full research report on Hemo Depot here >>> Other noteworthy reports we are featuring today include The Boeing Company, and Vale S.A.. Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared
+40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation. See Stocks Free >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.